• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Wesana Health Hldgs Inc (OP: WSNAF )

    0.0040 UNCHANGED
    Streaming Delayed Price Updated: 2:51 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 33
    Open 0.0040
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0040
    Today's Range 0.0040 - 0.0040
    52wk Range 0.0025 - 0.0270
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
    First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
    Via Benzinga
    Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific
    Psychedelics drug developer Wesana Health Holdings Inc. (OTCQB: WSNAF) announced all matters discussed at the company’s annual general and special shareholders meeting of June 9 were approved by a... 
    Via Benzinga

    Performance

    YTD
    -24.53%
    -24.53%
    1 Month
    -27.27%
    -27.27%
    3 Month
    -47.37%
    -47.37%
    6 Month
    -69.23%
    -69.23%
    1 Year
    -63.64%
    -63.64%

    More News

    Read More
    Disney, Amgen, First Republic, Psychedelics: How One CEO's Universal Deal-Making Approach Shapes Industries
    Via Benzinga
    EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
    Via Benzinga
    What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
    Via Benzinga
    High-Profile Highs: How Celebrity Advocacy Is Transforming Society's Views On Psychedelics And Cannabis
    Via Benzinga
    Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
    Via Benzinga
    Lucy Scientific Shares Trading Higher On Asset Purchase Agreement Of Psychedelic Assets From Wesana Health
    Via Benzinga
    NGOs Raise Money To Help Stem Opioid Addiction With Psychedelics Program
    Via Benzinga
    Wesana Sells Clinic Management Services Organization To Strengthen Assets
    Via Benzinga
    4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
    Via Benzinga
    Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
    Via Benzinga
    Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage
    Via Benzinga
    Daniel Carcillo Explains How Wesana Health Is Using Psychedelics To Treat Traumatic Brain Injury
    Via Benzinga
    EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space
    Via Benzinga
    Wesana Health One Step Closer To Clinical Trials Of Psilocybin And CBD Based Treatment Of Brain Injury Related MDD
    Via Benzinga
    Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
    Via Benzinga
    Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
    Via Benzinga
    The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
    Via Benzinga
    Topics Death
    Exposures Death
    Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
    Via Benzinga
    There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
    Via Benzinga
    Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
    Via Benzinga
    Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out
    Via Benzinga
    Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.